Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Summary
Diabetic kidney disease (DKD) is a leading cause of chronic and end-stage kidney disease, affecting 25-40% of type 1 diabetes (T1D) patients and 5-40% of type 2 diabetes (T2D) patients. Despite standard treatments like ACE inhibitors and ARBs, many patients continue to develop DKD, indicating a need for better kidney protection. This study aims to evaluate the efficacy and safety of dapagliflozin combined with insulin in early DKD patients with T1DM, using ACEi/ARB as standard treatment, to provide new insights into kidney protection and support precision medicine goals.
Official title: Efficacy and Mechanism of Dapagliflozin Combined With Insulin in the Treatment of Early Diabetic Nephropathy in Patients With Type 1 Diabetes
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2024-07-01
Completion Date
2026-10-01
Last Updated
2024-08-01
Healthy Volunteers
No
Conditions
Interventions
dapagliflozin
dapagliflozin 5 MG/10 MG once daily
ACE inhibitor
ACE inhibitor
Locations (1)
Nanjing Medical University First Affiliated Hospital
Nanjing, Jiangsu, China